BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.
Marqeta (MQ) Q3 2024 Earnings Call Transcript
At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, this conference is being recorded.
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Nov 04, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Partici
Brightcove Inc. (BCOV) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ETCompany ParticipantsMarc DeBevoise - Chief Executive
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, investor relations. Please go ahead. Michael Horowicz-- Vice President,
Cautious Outlook on BioNTech SE: Strong Q3 Performance Overshadowed by Uncertain Future in Vaccine Sales and Oncology Pipeline
BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...
ETF Daily News4d
BioNTech SE (NASDAQ:BNTX) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat ...
Deutsche Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
Benzinga.com3mon
BioNTech (NASDAQ:BNTX) Stock Quotes, Forecast and News Summary
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current ...
Nasdaq19d
Guru Fundamental Report for BNTX - Benjamin Graham
Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...
Morningstar2d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Business Insider1d
Evercore ISI Remains a Hold on BioNTech SE (BNTX)
In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $110.00. The company’s shares closed yesterday at ...